SCA
APLS

Snowden Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Snowden Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,288
Closed -$354K – 1197
2024
Q3 		$354K Buy
12,288
+199
+2% +$7.37K 0.01% 920
2024
Q2 		$464K Buy
12,089
+3,191
+36% +$145K 0.01% 784
2024
Q1 		$523K Sell
8,898
-264
-3% -$16.8K 0.02% 743
2023
Q4 		$548K Sell
9,162
-288
-3% -$14.6K 0.02% 660
2023
Q3 		$359K Buy
9,450
+3,417
+57% +$150K 0.02% 791
2023
Q2 		$550K Buy
6,033
+179
+3% +$15.4K 0.02% 691
2023
Q1 		$386K Buy
+5,854
New +$338K 0.02% 842
2019
Q3 		– Sell
-10,914
Closed -$277K – 513
2019
Q2 		$277K Buy
+10,914
New +$222K 0.03% 423

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Snowden Capital Advisors's APLS Position: Q4 2024 in Review

Snowden Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 12,288 shares — an estimated $354K sold.

Snowden Capital Advisors first reported a position in APLS in Q2 2019 and held it in 8 quarters. The position peaked at $550K in Q2 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Snowden Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Snowden Capital Advisors sold 12,288 Apellis Pharmaceuticals shares in Q4 2024, an estimated $354K.
  • Snowden Capital Advisors first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 8 quarters.
  • Snowden Capital Advisors's Apellis Pharmaceuticals position peaked at $550K in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Snowden Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.